Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-octreotide PET
imaging in comparison with the current golden standard, 68Ga-DOTA-somatostatin analog PET, in
neuroendocrine tumor patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Collaborators:
NETwerk, Belgium University Hospital, Antwerp University Hospital, Ghent